{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T06:13:17Z","timestamp":1788415997843,"version":"build-2803163510"},"reference-count":54,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T00:00:00Z","timestamp":1788393600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Cardiovasc. Med."],"abstract":"<jats:p>Heart failure with preserved ejection fraction (HFpEF) disproportionately affects women and has emerged as one of the most prevalent forms of heart failure worldwide. Although the marked increase in HFpEF incidence after menopause is well recognized, the biological events that initiate disease development remain poorly defined. Most mechanistic and clinical investigations have focused on postmenopausal women or established HFpEF, leaving the menopausal transition comparatively underexplored despite growing evidence that it represents a period of accelerated cardiometabolic change. This review synthesizes current evidence on reproductive aging, cardiometabolic remodeling, and the pathophysiological mechanisms underlying HFpEF to examine whether perimenopause represents a critical window in the development of the female HFpEF phenotype. Evidence from longitudinal cohorts and mechanistic studies indicates that visceral and epicardial adiposity, insulin resistance, adverse lipid remodeling, systemic inflammation, endothelial dysfunction, coronary microvascular impairment, arterial stiffening, and early cardiac remodeling emerge or accelerate during the menopausal transition. These biological alterations closely parallel established mechanisms implicated in HFpEF pathogenesis. Building on prior clinical and experimental evidence identifying the menopausal transition as a period of cardiovascular remodeling and increasing cardiovascular risk, we develop a temporal framework for female HFpEF. This framework considers whether, in susceptible women, HFpEF-relevant biological changes may begin to accumulate during perimenopause, become progressively amplified after menopause, and ultimately contribute to clinically manifest disease. We further examine how reliance on binary reproductive classifications, recruitment of predominantly postmenopausal cohorts, and the limited integration of reproductive staging into cardiovascular research may have contributed to this early phase of disease remaining largely unrecognized. Reframing perimenopause as a critical period of cardiovascular remodeling shifts attention from treating established HFpEF to identifying opportunities for earlier prevention. Prospective longitudinal studies incorporating standardized reproductive staging, comprehensive cardiovascular phenotyping, and biomarker profiling are now needed to determine whether the menopausal transition represents the earliest identifiable window for preventing HFpEF in women.<\/jats:p>","DOI":"10.3389\/fcvm.2026.1948320","type":"journal-article","created":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T05:21:41Z","timestamp":1788412901000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Perimenopause as a potential window of cardiometabolic remodeling in heart failure with preserved ejection fraction: a missed opportunity for prevention"],"prefix":"10.3389","volume":"13","author":[{"given":"Faith Adedayo","family":"Adejumo","sequence":"first","affiliation":[{"name":"Department of Medicine and Surgery, Bowen University","place":["Iwo, Nigeria"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oluwayimika Oluwatobi","family":"Obielodan","sequence":"additional","affiliation":[{"name":"Department of Medicine and Surgery, Bowen University","place":["Iwo, Nigeria"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fiyinfoluwa","family":"Adetoye","sequence":"additional","affiliation":[{"name":"Department of Medicine and Surgery, Bowen University","place":["Iwo, Nigeria"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas","family":"Aderinto","sequence":"additional","affiliation":[{"name":"Department of Medicine and Surgery, Ladoke Akintola University of Technology","place":["Ogbomoso, Nigeria"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,9,3]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1038\/s41572-024-00540-y","article-title":"Heart failure with preserved ejection fraction","volume":"10","author":"Hamo","year":"2024","journal-title":"Nat Rev Dis Primers"},{"key":"B2","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1016\/j.ijcard.2020.01.003","article-title":"Heart failure with preserved ejection fraction: similarities and differences between women and men","volume":"304","author":"Pepine","year":"2020","journal-title":"Int J Cardiol"},{"key":"B3","doi-asserted-by":"publisher","first-page":"3859","DOI":"10.1093\/eurheartj\/ehz835","article-title":"Sex differences in heart failure","volume":"40","author":"Lam","year":"2019","journal-title":"Eur Heart J"},{"key":"B4","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1016\/j.jchf.2019.03.011","article-title":"Sex-Based differences in heart failure across the ejection fraction Spectrum: phenotyping, and prognostic and therapeutic implications","volume":"7","author":"Stolfo","year":"2019","journal-title":"JACC Heart Fail"},{"key":"B5","doi-asserted-by":"publisher","first-page":"862","DOI":"10.1016\/j.jchf.2019.05.015","article-title":"Health-Related quality of life in heart failure with preserved ejection fraction: the PARAGON-HF trial","volume":"7","author":"Chandra","year":"2019","journal-title":"JACC Heart Fail"},{"key":"B6","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1016\/j.jacc.2024.06.001","article-title":"Efficacy of semaglutide by sex in obesity-related heart failure with preserved ejection fraction: STEP-HFpEF trials","volume":"84","author":"Verma","year":"2024","journal-title":"J Am Coll Cardiol"},{"key":"B7","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1161\/CIRCULATIONAHA.118.034271","article-title":"Sex differences in cardiovascular pathophysiology: why women are overrepresented in heart failure with preserved ejection fraction","volume":"138","author":"Beale","year":"2018","journal-title":"Circulation"},{"key":"B8","doi-asserted-by":"publisher","first-page":"17455057221140209","DOI":"10.1177\/17455057221140209","article-title":"Sex differences in heart failure with preserved ejection fraction: from traditional risk factors to sex-specific risk factors","volume":"18","author":"Kaur","year":"2022","journal-title":"Womens Health (Lond)"},{"key":"B9","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.1161\/CIRCULATIONAHA.119.041886","article-title":"Research priorities for heart failure with preserved ejection fraction: national heart, lung, and blood institute working group summary","volume":"141","author":"Shah","year":"2020","journal-title":"Circulation"},{"key":"B10","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1038\/s41569-023-00926-7","article-title":"The menopausal transition period and cardiovascular risk","volume":"21","author":"Mehta","year":"2024","journal-title":"Nat Rev Cardiol"},{"key":"B11","doi-asserted-by":"publisher","first-page":"967","DOI":"10.1093\/eurheartj\/ehaa1044","article-title":"Cardiovascular health after menopause transition, pregnancy disorders, and other gynaecologic conditions: a consensus document from European cardiologists, gynaecologists, and endocrinologists","volume":"42","author":"Maas","year":"2021","journal-title":"Eur Heart J"},{"key":"B12","doi-asserted-by":"publisher","first-page":"1074","DOI":"10.1016\/j.jacc.2019.12.049","article-title":"Menopause-Related estrogen decrease and the pathogenesis of HFpEF: JACC review topic of the week","volume":"75","author":"Sabbatini","year":"2020","journal-title":"J Am Coll Cardiol"},{"key":"B13","doi-asserted-by":"publisher","first-page":"e506","DOI":"10.1161\/CIR.0000000000000912","article-title":"Menopause transition and cardiovascular disease risk: implications for timing of early prevention: a scientific statement from the American Heart Association","volume":"142","author":"El Khoudary","year":"2020","journal-title":"Circulation"},{"key":"B14","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1007\/s11883-025-01343-6","article-title":"Cardiovascular risk associated with menopause and menopause hormone therapy: a review and contemporary approach to risk assessment","volume":"27","author":"D'Costa","year":"2025","journal-title":"Curr Atheroscler Rep"},{"key":"B15","doi-asserted-by":"publisher","first-page":"1159","DOI":"10.1210\/jc.2011-3362","article-title":"Executive summary of the stages of reproductive aging workshop+10: addressing the unfinished agenda of staging reproductive aging","volume":"97","author":"Harlow","year":"2012","journal-title":"J Clin Endocrinol Metab"},{"key":"B16","doi-asserted-by":"publisher","first-page":"675","DOI":"10.3390\/biom14060675","article-title":"Perimenopause decreases SERCA2a activity in the hearts of a mouse model of ovarian failure","volume":"14","author":"Barry","year":"2024","journal-title":"Biomolecules"},{"key":"B17","doi-asserted-by":"publisher","first-page":"G49","DOI":"10.1093\/ejendo\/lvaf206","article-title":"European Society of Endocrinology clinical practice guideline for evaluation and management of menopause and the perimenopause","volume":"193","author":"Lumsden","year":"2025","journal-title":"Eur J Endocrinol"},{"key":"B18","doi-asserted-by":"publisher","first-page":"10172","DOI":"10.1038\/s41598-024-60373-3","article-title":"Chronicling menstrual cycle patterns across the reproductive lifespan with real-world data","volume":"14","author":"Cunningham","year":"2024","journal-title":"Sci Rep"},{"key":"B19","doi-asserted-by":"publisher","first-page":"e124865","DOI":"10.1172\/jci.insight.124865","article-title":"Changes in body composition and weight during the menopause transition","volume":"4","author":"Greendale","year":"2019","journal-title":"JCI Insight"},{"key":"B20","doi-asserted-by":"publisher","first-page":"2312885","DOI":"10.1080\/09513590.2024.2312885","article-title":"Obesity and menopause","volume":"40","author":"Palacios","year":"2024","journal-title":"Gynecol Endocrinol"},{"key":"B21","doi-asserted-by":"publisher","first-page":"3304","DOI":"10.1210\/JC.2015-2110","article-title":"Cardiovascular fat, menopause, and sex hormones in women: the SWAN cardiovascular fat ancillary study","volume":"100","author":"El Khoudary","year":"2015","journal-title":"J Clin Endocrinol Metab"},{"key":"B22","doi-asserted-by":"publisher","first-page":"101444","DOI":"10.1016\/j.ijcha.2024.101444","article-title":"Association of epicardial fat with cardiac structure and function and exercise capacity in heart failure with preserved ejection fraction: a systematic review and meta-analysis","volume":"54","author":"Fukuta","year":"2024","journal-title":"Int J Cardiol Heart Vasc"},{"key":"B23","doi-asserted-by":"publisher","first-page":"2013","DOI":"10.1002\/ehf2.14744","article-title":"Impact of epicardial adipose tissue on cardiac function and morphology in patients with diastolic dysfunction","volume":"11","author":"Schulz","year":"2024","journal-title":"ESC Heart Fail"},{"key":"B24","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1186\/s12944-024-02266-y","article-title":"Linking abnormal fat distribution with HFpEF and diastolic dysfunction: a systematic review, meta-analysis, and meta-regression of observational studies","volume":"23","author":"Fu","year":"2024","journal-title":"Lipids Health Dis"},{"key":"B25","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1016\/j.jacl.2022.11.008","article-title":"The independent associations of anti-m\u00fcllerian hormone and estradiol levels over the menopause transition with lipids\/lipoproteins: the study of Women's Health across the nation","volume":"17","author":"El Khoudary","year":"2023","journal-title":"J Clin Lipidol"},{"key":"B26","doi-asserted-by":"publisher","first-page":"1006","DOI":"10.1097\/GME.0000000000002245","article-title":"Low-density lipoprotein subclasses over the menopausal transition and risk of coronary calcification and carotid atherosclerosis: the SWAN heart and HDL ancillary studies","volume":"30","author":"El Khoudary","year":"2023","journal-title":"Menopause"},{"key":"B27","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1016\/j.cmet.2016.07.017","article-title":"Sex and gender: critical variables in Pre-clinical and clinical medical research","volume":"24","author":"Morselli","year":"2016","journal-title":"Cell Metab"},{"key":"B28","doi-asserted-by":"publisher","first-page":"442","DOI":"10.3389\/fendo.2019.00442","article-title":"Estrogen contributions to microvascular dysfunction evolving to heart failure with preserved ejection fraction","volume":"10","author":"Sickinghe","year":"2019","journal-title":"Front Endocrinol (Lausanne)"},{"key":"B29","doi-asserted-by":"publisher","first-page":"46","DOI":"10.14336\/AD.2022.0523","article-title":"The NO-cGMP-PKG axis in HFpEF: from pathological mechanisms to potential therapies","volume":"14","author":"Cai","year":"2023","journal-title":"Aging Dis"},{"key":"B30","doi-asserted-by":"publisher","first-page":"4692","DOI":"10.1210\/jc.2012-2244","article-title":"Endothelial function is impaired across the stages of the menopause transition in healthy women","volume":"97","author":"Moreau","year":"2012","journal-title":"J Clin Endocrinol Metab"},{"key":"B31","doi-asserted-by":"publisher","first-page":"626","DOI":"10.1097\/GME.0000000000001755","article-title":"Abdominal visceral adipose tissue over the menopause transition and carotid atherosclerosis: the SWAN heart study","volume":"28","author":"Samargandy","year":"2021","journal-title":"Menopause"},{"key":"B32","doi-asserted-by":"publisher","first-page":"e195","DOI":"10.3346\/jkms.2024.39.e195","article-title":"Arterial stiffness and heart failure with preserved ejection fraction","volume":"39","author":"Kim","year":"2024","journal-title":"J Korean Med Sci"},{"key":"B33","doi-asserted-by":"publisher","first-page":"1435677","DOI":"10.3389\/fcvm.2024.1435677","article-title":"The association between pulse wave velocity and heart failure: a systematic review and meta-analysis","volume":"11","author":"Esmaeili","year":"2024","journal-title":"Front Cardiovasc Med"},{"key":"B34","doi-asserted-by":"publisher","first-page":"100390","DOI":"10.1016\/j.ahjo.2024.100390","article-title":"Arterial stiffness assessment in coronary microvascular dysfunction and heart failure with preserved ejection fraction: an initial report from the WISE-CVD continuation study","volume":"41","author":"Rezaeian","year":"2024","journal-title":"Am Heart J Plus"},{"key":"B35","doi-asserted-by":"publisher","first-page":"102345","DOI":"10.1016\/j.jacadv.2025.102345","article-title":"The role of coronary microvascular dysfunction in heart failure with preserved ejection fraction","volume":"4","author":"Tzoumas","year":"2025","journal-title":"JACC Adv"},{"key":"B36","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1007\/s10741-023-10362-x","article-title":"The prevalence of coronary microvascular dysfunction (CMD) in heart failure with preserved ejection fraction (HFpEF): a systematic review and meta-analysis","volume":"29","author":"Lin","year":"2024","journal-title":"Heart Fail Rev"},{"key":"B37","doi-asserted-by":"publisher","first-page":"2063","DOI":"10.1002\/ehf2.14626","article-title":"Impact of coronary microvascular dysfunction in heart failure with preserved ejection fraction: a meta-analysis","volume":"11","author":"D'Amario","year":"2024","journal-title":"ESC Heart Fail"},{"key":"B38","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1007\/s10741-024-10479-7","article-title":"Focusing on microvascular function in heart failure with preserved ejection fraction","volume":"30","author":"Velollari","year":"2025","journal-title":"Heart Fail Rev"},{"key":"B39","doi-asserted-by":"publisher","first-page":"1810","DOI":"10.1016\/j.jacc.2023.01.049","article-title":"Heart failure with preserved ejection fraction: JACC scientific statement","volume":"81","author":"Borlaug","year":"2023","journal-title":"J Am Coll Cardiol"},{"key":"B40","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1515\/jtim-2026-0043","article-title":"Inflammation, metabolism, and aging in heart failure with preserved ejection fraction: mechanisms and treatment perspectives","volume":"14","author":"Teng","year":"2026","journal-title":"J Transl Int Med"},{"key":"B41","doi-asserted-by":"publisher","first-page":"1166","DOI":"10.1097\/GME.0000000000001815","article-title":"Associations between menopause, cardiac remodeling, and diastolic function: the CARDIA study","volume":"28","author":"Ying","year":"2021","journal-title":"Menopause"},{"key":"B42","doi-asserted-by":"publisher","first-page":"e3994","DOI":"10.21769\/BioProtoc.3994","article-title":"Development of a chemical reproductive aging model in female rats","volume":"11","author":"Pestana-Oliveira","year":"2021","journal-title":"Bio Protoc"},{"key":"B43","doi-asserted-by":"publisher","first-page":"e13290","DOI":"10.1111\/apha.13290","article-title":"Cardiac changes during the peri-menopausal period in a VCD-induced murine model of ovarian failure","volume":"227","author":"Fernandes","year":"2019","journal-title":"Acta Physiol (Oxf)"},{"key":"B44","doi-asserted-by":"publisher","first-page":"H1461","DOI":"10.1152\/ajpheart.00555.2019","article-title":"Using 4-vinylcyclohexene diepoxide as a model of menopause for cardiovascular disease","volume":"318","author":"Konhilas","year":"2020","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"B45","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1016\/j.lfs.2019.04.007","article-title":"Ovarian failure induced by 4-vinylcyclohexene diepoxide worsens the autonomic cardiovascular response to chronic unpredictable stress in rats","volume":"226","author":"Lorenzon","year":"2019","journal-title":"Life Sci"},{"key":"B46","doi-asserted-by":"publisher","first-page":"1712","DOI":"10.1152\/physiol.2024.39.S1.1712","article-title":"Female mice with menopause exhibit coronary microvascular disease","volume":"39","author":"Yang","year":"2024","journal-title":"Physiol"},{"key":"B47","doi-asserted-by":"publisher","first-page":"23","DOI":"10.36346\/sarjmb.2026.v07i02.002","article-title":"The relationship between advanced inflammatory markers and telomere length in cardiac remodeling induced by VCD-induced ovarian failure in female rats","volume":"7","author":"Azeez","year":"2026","journal-title":"SAR J Med Biochem"},{"key":"B48","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1016\/j.hfc.2021.02.001","article-title":"Pathophysiology of heart failure with preserved ejection fraction","volume":"17","author":"Youn","year":"2021","journal-title":"Heart Fail Clin"},{"key":"B49","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1177\/026119291504300606","article-title":"Conditions and possible mechanisms of VCD-induced ovarian failure","volume":"43","author":"Liu","year":"2015","journal-title":"Altern Lab Anim"},{"key":"B50","doi-asserted-by":"publisher","first-page":"105680","DOI":"10.1016\/j.yhbeh.2025.105680","article-title":"Hormonal fluctuations in rodent models using 4-vinylcyclohexene diepoxide: a systematic review and meta-analysis","volume":"168","author":"Mashimo","year":"2025","journal-title":"Horm Behav"},{"key":"B51","doi-asserted-by":"publisher","first-page":"1287","DOI":"10.1007\/s00392-024-02396-4","article-title":"Heart failure with preserved ejection fraction: diagnosis, risk assessment, and treatment","volume":"113","author":"Von Haehling","year":"2024","journal-title":"Clin Res Cardiol"},{"key":"B52","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1007\/s00059-022-05124-8","article-title":"The future of heart failure with preserved ejection fraction: deep phenotyping for targeted therapeutics","volume":"47","author":"Heinzel","year":"2022","journal-title":"Herz"},{"key":"B53","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1097\/GME.0000000000002028","article-title":"The 2022 hormone therapy position statement of the north American menopause society","volume":"29","year":"2022","journal-title":"Menopause"},{"key":"B54","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1186\/s40842-026-00319-y","article-title":"Concomitant use of SGLT2 inhibitors and GLP-1 receptor agonists in patients with heart failure","volume":"12","author":"Khademi","year":"2026","journal-title":"Cardiovasc Diabetol Endocrinol Rep"}],"container-title":["Frontiers in Cardiovascular Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcvm.2026.1948320\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T05:21:42Z","timestamp":1788412902000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcvm.2026.1948320\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,3]]},"references-count":54,"alternative-id":["10.3389\/fcvm.2026.1948320"],"URL":"https:\/\/doi.org\/10.3389\/fcvm.2026.1948320","relation":{},"ISSN":["2297-055X"],"issn-type":[{"value":"2297-055X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,3]]},"article-number":"1948320"}}